P38 mitogen-activated protein kinase in beryllium-induced dendritic cell activation

Human Immunology

Volumn 75, Issue 12, 2014, Pages 1155-1162

  Li, L ^a,b   Huang, Z ^a   Gillespie, M ^a   Mroz, P M ^a   Maier, L A ^a,b,c  

^a DEPARTMENT OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c Food Science and Human Nutrition   (United States)

Author keywords

CBD; DCs; Lymphocyte proliferation; NF B; P38MAPK

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; BERYLLIUM; CD40 ANTIGEN; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HAPTEN; HLA DP ANTIGEN; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 4; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE P38; NICKEL; TUMOR NECROSIS FACTOR ALPHA; BERYLLIUM SULFATE; CYTOKINE; IMIDAZOLE DERIVATIVE; PYRIDINE DERIVATIVE;

ADULT; AGED; ARTICLE; BERYLLIOSIS; BERYLLIUM SENSITIZATION; CELL ACTIVATION; CELL MATURATION; CELL PROLIFERATION; CHRONIC BERYLLIUM DISEASE; CLINICAL ARTICLE; CLINICAL EVALUATION; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; DOWN REGULATION; DRUG SENSITIZATION; FEMALE; HUMAN; LUNG GRANULOMA; LYMPHOCYTE PROLIFERATION; MALE; MIDDLE AGED; MONOCYTE DERIVED DENDRITC CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; T LYMPHOCYTE; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CHRONIC GRANULOMATOUS DISEASE; DRUG EFFECTS; ENZYME ACTIVATION; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; PHOSPHORYLATION;

AGED; ANTIGENS, CD40; BERYLLIOSIS; BERYLLIUM; CELL PROLIFERATION; CYTOKINES; DENDRITIC CELLS; ENZYME ACTIVATION; FEMALE; GRANULOMATOUS DISEASE, CHRONIC; HUMANS; IMIDAZOLES; INTERFERON-GAMMA; LYMPHOCYTE ACTIVATION; MALE; MAP KINASE SIGNALING SYSTEM; MIDDLE AGED; NF-KAPPA B; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PYRIDINES; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84927511148     PISSN: 01988859     EISSN: 18791166     Source Type: Journal    
DOI: 10.1016/j.humimm.2014.10.010     Document Type: Article

References (48)

1. Newman L.S., Maier L.A. Beryllium disease. Interstitial Lung Disease 2003, 435-451. B.C. Decker Inc., Hamilton. M.I. Schwarz, T.E. King (Eds.).
2. Henneberger P.K., Cumro D., Deubner D.D., Kent M.S., McCawley M., Kreiss K. Beryllium sensitization and disease among long-term and short-term workers in a beryllium ceramics plant. Int Arch Occup Environ Health 2001, 74:167-176.
3. Kreiss K., Mroz M.M., Ahen B., Martyny J.W., Newman L.S. Epidemiology of beryllium sensitizations and disease in nuclear workers. Am Rev Respir Dis 1993, 148:985-991.
4. Newman L.S., Mroz M.M., Maier L.A., Danilof E.M., Balkissoon R. Efficacy of serial medical surveillance for chronic beryllium disease in a beryllium machining plant. J Occup Environ Med 2001, 43:231-237.
5. Fontenot A.P., Canavera S.J., Gharavi L., Newman L.S., Kotzin B.L. Target organ localization of CD4+T cells in patients with chronic beryllium disease. J Clin Invest 2002, 110:1473-1482.
6. Tinkle S.S., Kittle L.A., Schumacher B.A., Newman L.S. Beryllium induces IL-2 and IFN-γ in berylliosis. J Immunol 1997, 158:518-526.
7. Maier L.A., Sawyer R.T., Tinkle S.S., Barker E.A., Balkissoon R., Rose C., et al. IL-4 fails to regulate in vitro beryllium-induced cytokines in berylliosis. Eur Respir J 2001, 17:403-415.
8. Richeldi L., Sorrentino R., Saltini C. HLA-DPB1 glutamate 69: a genetic marker of beryllium disease. Science 1993, 262:242-244.
9. Maier L.A., McGrath D.S., Sato H., Lympany P., Welsh K., Du Bois R., et al. Influence of MHC class II in susceptibility to beryllium sensitization and chronic beryllium disease. J Immunol 2003, 171:6910-6918.
10. Rossman M.D., Stubbs J., Chung Lee W.H.A., Argyris E., Magira E., Monos D. Human leukocyte antigen Class II amino acid epitopes: susceptibility and progression markers for beryllium hypersensitivity. Am J Respir Crit Care Med 2002, 165(6):788-794.
11. McCanlies E.C., Ensey J.S., Schuler C.R., Kreiss K., Weston A. The association between HLA-DPB1Glu69 and chronic beryllium disease and beryllium sensitization. Am J Ind Med 2004, 46:95-103.
12. Wang Z., Farris G.M., Newman L.S., Shou Y., Maier L.A., Smith H.N., et al. Beryllium sensitivity is linked to HLA-DP genotype. Toxicology 2001, 165(1):27-38.
13. Fontenot A.P., Torres M., Marshall W.H., Newman L.S., Kotzin B.L. Beryllium presentation to CD4+ T cells underlies disease-susceptibility HLA-DP alleles in chronic beryllium disease. PNAS 2000, 97:12717-12722.
14. Hart D.N.J. Dendritic cells: unique leukocyte population which control the primary immune response. Blood 1997, 90:3245-3287.
15. Banchereau J., Steinman R.M. Dendritic cells and the control of immunity. Nature 1998, 392:245-252.
16. Cella M., Sallusto F., Lanzavecchia A. Origin, maturation and antigen presenting function of dendritic cells. Curr Opin Immunol 1997, 9:10-16.
17. Cella M., Engering A., Pinet V., Pieters J., Lanzavecchia A. Inflammatory stimuli induce accumulation of MHC class II complexes on dendritic cells. Nature 1997, 388:782-786.
18. Sallusto F., Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor. J Exp Med 1994, 179:1109-1118.
19. Sallusto F., Cella M., Danieli C., Lanzavecchia A. Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products. J Exp Med 1995, 182:389-400.
20. Aiba S., Manome H., Yoshino Y., Tagami H. In vitro treatment of human transforming growth factor-1-treated monocyte-derived dendritic cells with haptens can induce the phenotypic and functional changes similar to epidermal Langerhans cells in the initiation phase of allergic contact sensitivity reaction. Immunology 2000, 101:68-75.
21. Aiba S., Terunuma A., Manome H., Tagami H. Dendritic cells differently respond to haptens and irritants by their production of cytokines and expression of co-stimulatory molecules. Eur J Immunol 1997, 27:3031-3038.
22. Boisleve F., Kerdine-Romer S., Pallardy M. Implication of the MAPK pathways in the maturation of human dendritic cells induced by nickel and TNF-alpha. Toxicology 2005, 206:233-244.
23. Aiba S., Manome H., Nakagawa S., Mollah Z.U., Mizuashi M., Ohtani T., et al. P38 Mitogen-activated protein kinase and extracellular signal-regulated kinases play distinct roles in the activation of dendritic cells by two representative haptens, NiCl2 and 2,4-dinitrochlorobenzene. J Invest Dermatol 2003, 120:390-399.
24. Alessi D.R., Cuenda A., Cohen P., Dudley D.T., Saltiel AR. PD 098059 is a specific inhibitor of activation of mitogen-activated protein kinase kinase in vitro and in vivo. J Biol Chem 1995, 270:27489-27494.
25. Lee J.C., Laydon J.T., McDonnell P.C., et al. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 1994, 372:739-746.
26. Ade N., Antonios D., Kerdine-Romer S., Boisleve F., Rousset F., et al. NF-kappaB plays a major role in the maturation of human dendritic cells induced by NiSO(4) but not by DNCB. Toxicol Sci 2007, 99:488-501.
27. Li L., Reinhardt P., Schmitt A., Barth T.F., Greiner J., Ringhoffer M., et al. Cancer Immunol Immunother 2005, 54(7):685-693.
28. Bunce M., O'Neill C.M., Barnardo M.C., et al. Phototyping: comprehensive DNA typing for HLA-A, B, C, DRB1, DRB3, DRB4, DRB5 and DQB1 by PCR with 144 primer mixes utilizing sequence-specific primers (PCR-SSP). Tissue Antigens 1995, 46:355-367.
29. Gilchrist F.C., Bunce M., Lympany P.A., Welsh K.I., du Bois R.M. Comprehensive HLA-DP typing using polymerase chain reaction with sequence-specific primers and 95 sequence-specific primer mixes. Tissue Antigens 1998, 51:51-61.
30. Sawyer R.T., Parsons C.E., Fontenot A.P., Maier L.A., Gillespie M.M., Gottschall E.B., et al. Beryllium-induced tumor necrosis factor-α production by CD4+ T cells is mediated by HLA-DP. Am J Respir Cell Mol Biol 2004, 31:122-130.
31. Sawyer R.T., Doherty D., Schumacher B., Newman L.S. Beryllium-stimulated in vitro migration of peripheral blood lymphocytes. Toxicology 1999, 138:155-163.
32. Chaudhary A., Sauer N., Gupta G. Beryllium-specific immune response in primary cells from healthy individuals. Toxicology 2004, 201:9-19.
33. Arrighi J.F., Rebsamen M., Rousset F., Kindler V., Hauser C. A critical role for p38 mitogen-activated protein kinase in the maturation of human blood derived dendritic cells induced by lipopolysaccharide, TNF-alpha, and contact sensitizers. J Immunol 2001, 166:3837-3845.
34. Lee J.Y., Taylor L., King B., Scott P., Rossman M. Beryllium, an adjuvant that promotes gamma interferon production. Infect Immun 2000, 68(7):4032-4039.
35. Huang H., Meyer K.C., Kubai L., Auerbach R. An immune model of beryllium-induced pulmonary granulomata in mice. Histopathology, immune reactivity, and flow-cytometric analysis of bronchoalveolar lavage-derived cells. Lab Invest 1992, 67(1):138-146.
36. Barna B.P., Deodhar S.D., Chiang T., Gautam S., Edinger M. Experimental beryllium-induced lung disease: I. Differences in immunologic response to beryllium compounds in strains 2 and 13 guinea pigs. Int Arch Allergy Appl Immunol 1984, 73(1):42-48.
37. Tarantino-Hutchison L.M., Sorrentino C., Nadas A., Zhu Y., Rubin E.M., Tinkle S.S., et al. Genetic determinants of sensitivity to beryllium in mice. J Immunotoxicol 2009, 6(2):130-135.
38. Lehnert N., Gary R., Marrone B., Lehnert B. Inhibition of normal human lung fibroblast growth by beryllium. Toxicology 2001, 160:119-127.
39. Craig R., Larkin A., Mingo A.M., Thuerauf D.J., Andrews C., McDonough P.M., et al. p38 MAPK and NFkappa B collaborate to induce interleukin-6 gene expression and release. Evidence for a cytoprotective autocrine signaling pathway in a cardiac myocyte model system. J Biol Chem 2000, 275:23814-23824.
40. Schmidt M., Raghavan B., Muller V., Vogl T., Fejer G., Tchaptchet S., et al. Crucial role for human Toll-like receptor 4 in the development of contact allergy to nickel. Nat Immunol 2010, 11:814-819.
41. Potnis Pushya A., Dutta Debargh K., Wood Steven C. Toll-like receptor 4 signaling pathway mediates proinflammatory immune response to cobalt-alloy particles. Cell Immunol 2013, 282:53-65.
42. Rachmawati Dessy, Bontkes Hetty J., Verstege Marleen I., Muris Joris, von Blomberg B.Mary, Scheper Rik J. Transition metal sensing by Toll-like receptor-4: next to nickel, cobalt and palladium are potent human dendritic cell stimulators. Contact Dermatitis 2013, 68(6):331-338.
43. Rothenberg M.E. Innate sensing of nickel. Nat Immunol 2010, 11:781-782.
44. Pajarinen J., Mackiewicz Z., Pöllänen R., Takagi M., Epstein N.J., Ma T., et al. Titanium particles modulate expression of Toll-like receptor proteins. J Biomed Mater Res A 2010, 92(4):1528-1537.
45. Hirayama T., Tamaki Y., Takakubo Y., Iwazaki K., Sasaki K., Ogino T., et al. Toll-like receptors and their adaptors are regulated in macrophages after phagocytosis of lipopolysaccharide-coated titanium particles. J Orthop Res 2011, 29(7):984-992.
46. Huang J., Cui H., Peng X., Fang J., Zuo Z., Deng J., et al. Downregulation of TLR4 and 7 mRNA expression levels in broiler's spleen caused by diets supplemented with nickel chloride. Biol Trace Elem Res 2014, Mar 19. [Epub ahead of print].
47. Newman L.S. Current concepts: occupational illness. N Engl J Med 1995, 333:1128-1134.
48. Rastogi R., Du W., Ju D., Pirockinaite G., Liu Y., Nunez G., et al. Dysregulation of p38 and MKP-1 in response to NOD1/TLR4 stimulation in sarcoid bronchoalveolar cells. Am J Respir Crit Care Med 2011, 183:500-510.